双黄连粉针临床安全应用的探讨

Clinical safety study of Shuanghuanglian powder injection

目的：探讨双黄连粉针的临床安全应用。方法：通过对562例应用双黄连粉针静脉滴注患者进行分组临床观察,评价其安全性。A组选择无双黄连过敏史者180例给予常规剂量应用双黄连粉针,其静脉滴注速度为每分钟40~80滴。B组选择无任何药物及食物过敏史并排除年老体弱者382例给予常规剂量应用双黄连粉针,其静脉滴注速度为每分钟30~40滴。结果：B组不良反应发生率明显低于A组,其差异有统计学意义（P〈0.05）。结论：双黄连粉针的临床安全性与病例的选择及静脉滴注速度密切相关。

Objective：To explore the clinical safety application of Shuanghuanglian powder injection. Methods：Evaluate their safety through clinical observation of 562 patients who were treated by intravenous infusion of Shuanghuanglian powder injection. Group A, 180 patients with no drug sensitivity, were treated by normal dose, the speed of intravenous infusion was 40-80 drop/minute. Group B, 382 patients with no drug and food sensitivity and to exclude the elderly and infirm were given normal dose of Shaunghuanglian powder injection, the speed of intravenous infusion was 30-40 drop/minute. Results：The adverse reactions of group B was significantly lower than the group A, the difference was significant （P 0.05）. Conclusion：The clinical safety of Shuanghuanglian powder injection is closely linked with the patient and the ravenous infusion rate.